Showing results (2411-2420 of 2,774) with videos related to

Sort By:
Pageof 278
Transfusion|August 20, 2014
Trends in red blood cell transfusion and 30-day mortality among hospitalized patientsNareg H Roubinian, Gabriel J Escobar, Vincent Liu, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2010
Indazole derivatives as novel bradykinin B1 receptor antagonistsVera Bodmer-Narkevitch, Neville J Anthony, Victoria Cofre, et al.
Transfusion|October 26, 2011
Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) studyRitchard G Cable, Simone A Glynn, Joseph E Kiss, et al.
Antonie Van Leeuwenhoek|October 26, 1999
Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trialsC Dunne, L Murphy, S Flynn, et al.
The Lancet. HIV|October 2, 2015
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trialChad J Achenbach, Lambert Assoumou, Steven G Deeks, et al.
JMIR Public Health and Surveillance|October 29, 2024
Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Canada: Longitudinal Trend AnalysisScott A Wu, Alan G Soetikno, Egon A Ozer, et al.
JMIR Public Health and Surveillance|July 16, 2024
Surveillance Metrics and History of the COVID-19 Pandemic in Central Asia: Updated Epidemiological AssessmentAlexander L Lundberg, Egon A Ozer, Scott A Wu, et al.
JMIR Public Health and Surveillance|April 3, 2024
Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in the Middle East and North Africa: Longitudinal Trend AnalysisAlan G Soetikno, Alexander L Lundberg, Egon A Ozer, et al.
JMIR Public Health and Surveillance|April 3, 2024
Updated Surveillance Metrics and History of the COVID-19 Pandemic (2020-2023) in Europe: Longitudinal Trend AnalysisAlexander L Lundberg, Scott A Wu, Alan G Soetikno, et al.
The Journal of Infectious Diseases|December 12, 1997
Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study GroupE L Murphy, S A Glynn, J Fridey, et al.
Pageof 278